Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Liraglutide in T2DM on Metformin
NCT01296412Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2011
- Primary completion
- Feb 2012
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Hemoglobin A1c at 26 weeks. Started Mar 2011; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01296412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01296412.